Regenxbio Inc (RGNX) financials
Regenxbio revenue and earnings by year
Regenxbio's revenue was $170 million in the fiscal year to December 31, 2025, up 104.5% from the year before. Net income was -$194 million, -113.8% of revenue. Since the fiscal year to December 31, 2016, revenue has grown 49.4% a year on average.
Fiscal years, each labelled by the calendar year it ended in.
Income statement, the last 10 fiscal years
| Fiscal year to | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 170 | 83 | 90 | 113 | 470 | 155 | 35 | 219 | 10 | 5 |
| Revenue growth | 104.5% | -7.7% | -19.9% | -76.0% | 204.3% | 338.7% | -83.9% | 2002.4% | 126.5% | — |
| Gross profit | 150 | 50 | 53 | 58 | 419 | 119 | 27 | 209 | 9 | 4 |
| Gross margin | 88.1% | 59.7% | 58.8% | 51.6% | 89.0% | 76.9% | 76.6% | 95.6% | 83.6% | 81.2% |
| Operating income | -161 | -233 | -268 | -263 | 160 | -119 | -149 | 88 | -76 | -65 |
| Operating margin | -94.6% | -280.0% | -297.1% | -233.2% | 34.0% | -77.1% | -422.9% | 40.3% | -730.2% | -1423.8% |
| Net income | -194 | -227 | -263 | -280 | 128 | -111 | -95 | 100 | -73 | -63 |
| Net margin | -113.8% | -272.5% | -292.0% | -248.7% | 27.2% | -72.0% | -268.9% | 45.7% | -704.0% | -1372.1% |
| Diluted EPS | -$3.76 | -$4.59 | -$6.02 | -$6.50 | $2.91 | -$3.00 | -$2.59 | $2.89 | -$2.47 | -$2.39 |
| Free cash flow | -126 | -176 | -228 | -238 | 135 | -81 | -119 | 91 | -65 | -57 |
Diluted EPS is stated in today's shares (adjusted for every split since). Quarterly statements and the income statement as a flow chart are in the app: open RGNX in Markets.
How Regenxbio makes money
Revenue by segment in the quarter to June 30, 2026, as the company reports it.
| Segment | Revenue | Share |
|---|---|---|
| Abb Vie Development Milestone | $100M | 92.6% |
| Nippon Shinyaku Services | $3.72M | 3.4% |
| Itvisma Royalties | $2.09M | 1.9% |
| Zolgensma Royalties | $1.75M | 1.6% |
| Other Service Revenue | $458K | 0.4% |
See also: RGNX returns
No forecast, no recommendation. This page describes Regenxbio Inc from published data; it is not advice to buy, sell or hold any security.
Figures as of the close on Oct 30, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.